Kodiak Files New $350M At-The-Market Program With J.P. Morgan
KOD has more than doubled off its 52-week low of $15.833.
Summary
Kodiak registered a new $350 million at-the-market stock sale program with J.P. Morgan, replacing an exhausted prior shelf. No shares have been sold; it gives the cash-burning biotech a standing mechanism to raise money into post-Phase 3 strength.
Key Events · Financing and Capital Events · KOD
-
New $350M ATM Program Established
A distribution agreement dated October 20, 2026 with J.P. Morgan Securities LLC allows Kodiak to sell up to $350 million of common stock from time to time as agent or principal. No shares have been sold under it.
-
Dilution If Fully Drawn
At the $91.35 last reported sale price on October 19, 2026, full use would mean about 3,831,417 new shares versus 62,830,860 outstanding as of June 30, 2026 — roughly 6% dilution. Actual share count and proceeds depend on prices at the time of sale.
-
Agent Fees and Expenses
J.P. Morgan earns up to 3% of gross proceeds; estimated offering expenses excluding commissions are about $400,000.
-
Prior Shelf Replaced
The new S-3ASR replaces the May 2023 shelf (File No. 333-271946), which has terminated after $184 million of its $350 million was sold; $18,293.20 of unused registration fees were carried over.
Analysis · KOD · Life Sciences
Kodiak has put a fresh $350 million at-the-market shelf in place through J.P. Morgan, replacing a prior shelf that has been fully drawn down and terminated. No shares have been sold yet — this is authorization to drip-feed stock into the market over time, at management's discretion, at up to a 3% agent commission. Timing matters here: the company carried a going-concern warning as of its Q2 filing, and this gives it a ready mechanism to raise cash into the strength of the September Phase 3 DAYBREAK win that sent the stock from roughly $38 to $54 and beyond. The overhang is real — if fully used at the $91.35 reference price it would add about 3.8 million shares to the 62.8 million outstanding, roughly 6% dilution — but the program is discretionary and the company is not obligated to sell any shares.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 29.2% of the 1466 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KOD was trading at $92.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $15.83 to $104.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.